Nymox Pharma Resolves Bahamas Litigation
Ticker: NYMXF · Form: 6-K · Filed: Mar 28, 2024 · CIK: 1018735
| Field | Detail |
|---|---|
| Company | Nymox Pharmaceutical CORP (NYMXF) |
| Form Type | 6-K |
| Filed Date | Mar 28, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: legal, resolution, bahamas
Related Tickers: NYMX
TL;DR
Nymox Pharma got court order to settle ex-employee lawsuit in Bahamas.
AI Summary
Nymox Pharmaceutical Corporation announced on March 27, 2024, that it has secured a formal order from the Bahamas Supreme Court to resolve litigation initiated by its former employees. This development pertains to a dispute that has now been officially settled through the court's order.
Why It Matters
The resolution of this legal dispute removes a potential overhang for Nymox Pharmaceutical Corporation, allowing the company to focus on its core business operations and strategic initiatives.
Risk Assessment
Risk Level: low — The filing reports the resolution of a legal matter, which is generally a positive development and reduces uncertainty.
Key Players & Entities
- Nymox Pharmaceutical Corporation (company) — Registrant
- Bahamas Supreme Court (company) — Court involved in litigation
- March 27, 2024 (date) — Date of press release
FAQ
What was the nature of the litigation resolved by the Bahamas Supreme Court?
The litigation was brought by the Company's terminated ex-employees.
When did Nymox Pharmaceutical Corporation announce the resolution?
Nymox Pharmaceutical Corporation issued a press release announcing the resolution on March 27, 2024.
What is the filing form used for this announcement?
The filing form used is a Form 6-K.
What is Nymox Pharmaceutical Corporation's principal executive office address?
The principal executive office is located at Bay & Deveaux Streets, Nassau, The Bahamas.
Does Nymox Pharmaceutical Corporation file annual reports under Form 20-F or 40-F?
Nymox Pharmaceutical Corporation files annual reports under cover of Form 20-F.
Filing Stats: 238 words · 1 min read · ~1 pages · Grade level 13.4 · Accepted 2024-03-28 13:03:08
Filing Documents
- nymox_6k.htm (6-K) — 11KB
- nymox_ex991.htm (EX-99.1) — 2KB
- nymox_ex991img1.jpg (GRAPHIC) — 257KB
- nymox_ex991img2.jpg (GRAPHIC) — 250KB
- 0001640334-24-000510.txt ( ) — 712KB
From the Filing
nymox_6k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the Month of March, 2024 Commission File Number: 001-12033 Nymox Pharmaceutical Corporation (Translation of registrant's name into English) Bay & Deveaux Streets, Nassau, The Bahamas (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F Form 40-F On March 27, 2024, Nymox Pharmaceutical Corporation (the "Company") issued a press release announcing that the Company successfully obtained a formal order from the Bahamas Supreme Court resolving the Bahamas litigation brought by the Company's terminated ex-employees. This press release is furnished as Exhibit 99.1 to this report on Form 6-K and shall not be deemed to be "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. EXHIBIT INDEX Exhibit No. Description 99.1 Press Release of Nymox Pharmaceutical Corporation, dated March 27, 2024 2 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: March 28, 2024 NYMOX PHARMACEUTICAL CORPORATION By: /s/ Paul Averback Name: Paul Averback Title: President and Chief Executive Officer 3